Athira Pharma

Athira Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer’s, Parkinson’s disease dementia, and dementia with Lewy bodies. We are a motivated, impassioned team committed to making a positive impact on human health.
Looking for a particular Athira Pharma employee's phone or email?

Athira Pharma Questions

News

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - Yahoo Finance

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 Yahoo Finance

Athira Pharma Announces Reverse Stock Split - GlobeNewswire

Athira Pharma Announces Reverse Stock Split GlobeNewswire

10-for-1 Reverse Split: Athira Pharma Restructures Shares to Maintain Nasdaq Listing, Boost Appeal - Stock Titan

10-for-1 Reverse Split: Athira Pharma Restructures Shares to Maintain Nasdaq Listing, Boost Appeal Stock Titan

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Athira Pharma to Participate in Upcoming June Conferences - Investing News Network

Athira Pharma to Participate in Upcoming June Conferences Investing News Network

Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium - Quiver Quantitative

Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium Quiver Quantitative

ACT-AD: Fosgonimeton in mild-to-moderate Alzheimer’s disease – first results of a randomized, placebo-controlled, 26-week Phase 2 proof-of-concept trial - Wiley

ACT-AD: Fosgonimeton in mild-to-moderate Alzheimer’s disease – first results of a randomized, placebo-controlled, 26-week Phase 2 proof-of-concept trial Wiley

Alzheimer’s Treatment Leverages Natural Repair Mechanism - Genetic Engineering and Biotechnology News

Alzheimer’s Treatment Leverages Natural Repair Mechanism Genetic Engineering and Biotechnology News

Athira Pharma Appoints Rachel Lenington as Chief Technology Officer - citybiz

Athira Pharma Appoints Rachel Lenington as Chief Technology Officer citybiz

M3 Biotechnology Announces Name Change to Athira Pharma, Inc. - PR Newswire

M3 Biotechnology Announces Name Change to Athira Pharma, Inc. PR Newswire

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action - FinancialContent

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action FinancialContent

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS - Frontiers

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS Frontiers

Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire

Athira Pharma to Present Data from First-in-Human Phase 1 GlobeNewswire

Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer - PR Newswire

Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer PR Newswire

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer - Yahoo Finance

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer Yahoo Finance

ATHA Stock Price and Chart — NASDAQ:ATHA - TradingView

ATHA Stock Price and Chart — NASDAQ:ATHA TradingView

Top Athira Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant